David Milligan V - 16 Jun 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Director
Issuer ticker: MDGL
Reported as of: 16 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2022, 06:30:25 UTC
Prior SEC filing: 21 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ Brian Lynch, as attorney-in-fact for David Milligan, M.D.

Key filing fact

David Milligan V filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 21 Jun 2022.

Key facts

This page summarizes David Milligan V's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2022, 06:30.

Change

Previous filing in this sequence was filed on 21 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +9,470
Change %
Price: $0.000000
Shares after: 9,470
Date: 16 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,470
Exercise price: $65.06
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.